[go: up one dir, main page]

WO2018140275A3 - Novel auristatin derivatives and related antibody-drug conjugates (adcs) and methods of preparation thereof - Google Patents

Novel auristatin derivatives and related antibody-drug conjugates (adcs) and methods of preparation thereof Download PDF

Info

Publication number
WO2018140275A3
WO2018140275A3 PCT/US2018/014167 US2018014167W WO2018140275A3 WO 2018140275 A3 WO2018140275 A3 WO 2018140275A3 US 2018014167 W US2018014167 W US 2018014167W WO 2018140275 A3 WO2018140275 A3 WO 2018140275A3
Authority
WO
WIPO (PCT)
Prior art keywords
adcs
preparation
methods
drug conjugates
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/014167
Other languages
French (fr)
Other versions
WO2018140275A2 (en
Inventor
Joachim Krüger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of WO2018140275A2 publication Critical patent/WO2018140275A2/en
Publication of WO2018140275A3 publication Critical patent/WO2018140275A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound according to the general Formula (8): wherein R1 is hydrogen or C1-C4 alkyl; R2 is C1-C4 alkyl, benzyl, or 1H-indol-3-ylmethyl; T is selected from the group consisting of -CH(OR3)-R4, -C(=O)-OR3, or -C(=O)-NR3 R5, wherein R3 is hydrogen or C1-C4 alkyl; R4 is phenyl; R5 is hydrogen or C1-C4 alkyl; L1 is R6-C(=O)-R7; where R6 is C1-C6 alkyl; R7 is a bond or NH-NH; L2 is a bond,, or; where n is 1-4; and Ab is an antibody or antigen-binding antibody fragment, and a process for preparing the same. In certain embodiments, Ab is an antibody or antigen-binding antibody fragment which binds to C4.4a.
PCT/US2018/014167 2017-01-26 2018-01-18 Novel auristatin derivatives and related antibody-drug conjugates (adcs) and methods of preparation thereof Ceased WO2018140275A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762450787P 2017-01-26 2017-01-26
US62/450,787 2017-01-26

Publications (2)

Publication Number Publication Date
WO2018140275A2 WO2018140275A2 (en) 2018-08-02
WO2018140275A3 true WO2018140275A3 (en) 2018-09-20

Family

ID=61868848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/014167 Ceased WO2018140275A2 (en) 2017-01-26 2018-01-18 Novel auristatin derivatives and related antibody-drug conjugates (adcs) and methods of preparation thereof

Country Status (1)

Country Link
WO (1) WO2018140275A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019042447A1 (en) * 2017-09-04 2019-03-07 江苏恒瑞医药股份有限公司 Novel toxin and method for preparing intermediate thereof
CN109912684A (en) * 2019-03-08 2019-06-21 联宁（苏州）生物制药有限公司 A kind of Preparation Method And Their Intermediate of the drug-linker MC-MMAF for antibody drug conjugates
CN109824759A (en) * 2019-03-08 2019-05-31 联宁（苏州）生物制药有限公司 A kind of Preparation Method And Their Intermediate of the drug-linker MC-MMAF for antibody drug conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150023989A1 (en) * 2011-12-14 2015-01-22 Seattle Genetics, Inc. New antibody drug conjugates (adcs) and the use thereof
US20150044238A1 (en) * 2005-07-07 2015-02-12 Seattle Genetics, Inc. Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the c-terminus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150044238A1 (en) * 2005-07-07 2015-02-12 Seattle Genetics, Inc. Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the c-terminus
US20150023989A1 (en) * 2011-12-14 2015-01-22 Seattle Genetics, Inc. New antibody drug conjugates (adcs) and the use thereof

Also Published As

Publication number Publication date
WO2018140275A2 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
MX2022003740A (en) Amide-linked, aminobenzazepine immunoconjugates, and uses thereof.
IL275757B2 (en) Steroids and their anti-inflammatory properties
WO2021022304A3 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
IL277242B1 (en) Antibodies that bind cd39 and uses thereof
MY198034A (en) Tumor-targeted agonistic cd28 antigen binding molecules
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
WO2018140275A3 (en) Novel auristatin derivatives and related antibody-drug conjugates (adcs) and methods of preparation thereof
MA32104B1 (en) Oxime derivatives as inhibitors of hsp90
MX2023008339A (en) Camptothecine antibody-drug conjugates and methods of use thereof.
CL2022003515A1 (en) cd28 antigen-binding agonist molecules targeting her2
NZ614857A (en) Bispecific antibodies and methods for production thereof
CL2012000824A1 (en) Antibody that specifically binds to the epitope that specifically binds to an epha2 receptor; conjugate of said antibody comprising a cytotoxic agent derived from a maytansinoid compound; method of preparing said conjugate; pharmaceutical composition.
RU2010133547A (en) ANTI-CLDN ANTIBODIES
MXPA05008705A (en) Pyridine derivatives as fungicidal compounds.
EP4382167A3 (en) Compounds comprising a linker for increasing transcyclooctene stability
MX2022007798A (en) Method for producing eribulin-based antibody-drug conjugate.
PE20090161A1 (en) MONOCLONAL ANTIBODIES ANTI CXCL13
CY1113184T1 (en) METHOD FOR THE PREPARATION OF THERAPEUTICALLY DIFFERENTIAL PRODUCERS OF TRIFINYLBUTENIUM
MA55284A (en) METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS
DK1740544T3 (en) 2 pyridinylcycloalkylcarboxamide derivatives useful as fungicides
WO2007144512A3 (en) Diazeniumdiolate derivatives, method for the preparation thereof, pharmaceutical compositions thereof, and use of same in the fields of hypertension and cardiovascular pathologies
EP4321523A3 (en) Hemiasterlin derivatives and antibody-drug conjugates including same
WO2007062056A3 (en) Silicon-germanium hydrides and methods for making and using same
DK2099812T3 (en) Process for the preparation of tagatose by high yield galactose isomerization
MA55283A (en) METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18715149

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18715149

Country of ref document: EP

Kind code of ref document: A2